Form 8-K

8-K — Amylyx Pharmaceuticals, Inc.

Accession: 0001193125-26-354793

Filed: 2026-08-18

Period: 2026-08-18

CIK: 0001658551

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — d184004d8k.htm (Primary)

EX-99.1 (d184004dex991.htm)

GRAPHIC (g184004ex99_1p10g1.jpg)

GRAPHIC (g184004ex99_1p11g1.jpg)

GRAPHIC (g184004ex99_1p12g1.jpg)

GRAPHIC (g184004ex99_1p13g1.jpg)

GRAPHIC (g184004ex99_1p14g1.jpg)

GRAPHIC (g184004ex99_1p15g1.jpg)

GRAPHIC (g184004ex99_1p16g1.jpg)

GRAPHIC (g184004ex99_1p17g1.jpg)

GRAPHIC (g184004ex99_1p1g1.jpg)

GRAPHIC (g184004ex99_1p2g1.jpg)

GRAPHIC (g184004ex99_1p3g1.jpg)

GRAPHIC (g184004ex99_1p4g1.jpg)

GRAPHIC (g184004ex99_1p5g1.jpg)

GRAPHIC (g184004ex99_1p6g1.jpg)

GRAPHIC (g184004ex99_1p7g1.jpg)

GRAPHIC (g184004ex99_1p8g1.jpg)

GRAPHIC (g184004ex99_1p9g1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: d184004d8k.htm · Sequence: 1

8-K

false 0001658551 0001658551 2026-08-18 2026-08-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 18, 2026

AMYLYX PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-41199

46-4600503

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

55 Cambridge Parkway, Suite 6W

Cambridge, Massachusetts

02142

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (617) 682-0917

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share

AMLX

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01.

Other Events.

On August 18, 2026, Amylyx Pharmaceuticals, Inc. (the “Company”) hosted a conference call with investors and analysts to discuss positive topline results from the LUCIDITY Phase 3 clinical trial evaluating the efficacy and safety of avexitide in participants with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery. Selected slides from the investor presentation used during the conference call are attached as Exhibit 99.1 to this Current Report on Form 8-K and are incorporated herein by reference.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

Exhibit

Number

Description

99.1

Presentation of the Company, dated August 18, 2026.

104

Cover Page Interactive Data File (embedded with the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMYLYX PHARMACEUTICALS, INC.

Date: August 18, 2026

By:

/s/ James M. Frates

James M. Frates

Chief Financial Officer

EX-99.1

Filename: d184004dex991.htm · Sequence: 2

EX-99.1

Exhibit 99.1 Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric

Hypoglycemia (PBH) Topline Data Conference Call August 18, 2026 Maggie, a mom and advocate living with post-bariatric hypoglycemia (PBH). Pancreatic islet cells

Opening Remarks Lindsey Allen Vice President, Investor Relations &

Communications at Amylyx

DISCLAIMER Statements contained in this presentation regarding matters

that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Because such statements are subject to risks and uncertainties, actual results may

differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, Amylyx’s expectations regarding: the therapeutic potential and safety of avexitide as a treatment for PBH;

expectations regarding the timing for NDA submission with the U.S. Food and Drug Administration; the potential benefits of regulatory designations held with the FDA; the plan to present data from LUCIDITY at an upcoming medical meeting; and

expectations regarding timing and preparedness for potential commercialization of avexitide, if approved. Any forward-looking statements in this presentation are based on management’s current expectations of future events and are subject to a

number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward- looking statements. Risks that contribute to the uncertain nature of the forward-looking

statements include: the success, cost, and timing of Amylyx’s program development activities, including ongoing and planned clinical trials, Amylyx’s ability to execute on its development and regulatory strategy, regulatory developments,

Amylyx’s cash runway and ability to fund operations, as well as the risks and uncertainties set forth in Amylyx’s United States Securities and Exchange Commission (SEC) filings, including Amylyx’s Annual Report on Form 10-K for the

year ended December 31, 2025, and subsequent filings with the SEC. All forward-looking statements contained in this presentation speak only as of the date on which they were made. Amylyx undertakes no obligation to update such statements to reflect

events that occur or circumstances that exist after the date on which they were made. 3

Phase 3 LUCIDITY Topline Data Camille Bedrosian, MD Chief Medical

Officer of Amylyx

LUCIDITY Met Its Primary and All Secondary Endpoints Consistent,

statistically significant, and clinically meaningful reductions in Level 2 and Level 3 hypoglycemic events vs. placebo An investigational, first-in-class GLP-1 receptor antagonist designed to reduce the exaggerated GLP-1 Avexitide response in

post-bariatric hypoglycemia (PBH) and restore activity to more physiological levels • FDA-Agreed Upon Primary Endpoint Met 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events vs. placebo (p=0.000003) • All

Secondary Endpoints Met Significant reductions in Level 2 (SMBG and CGM) and Level 3 events vs. placebo • Generally Well-Tolerated No treatment-related serious adverse events; most events mild or moderate Potential to be the first FDA-approved

therapy for PBH, a condition with a profound unmet medical need 5 SMBG: self-monitoring blood glucose; CGM: continuous glucose monitoring.

Phase 3 LUCIDITY Trial Design PHASE 3 LUCIDITY TRIAL DESIGN -

Multicenter, randomized, double-blind, placebo-controlled trial (N=78) 16-week Double-blind Treatment Period 32-week Open-label Extension Period 3:2 Randomization Avexitide 90 mg Once Daily N=78 21-day Eligibility Avexitide 90 mg Once Daily Safety

Follow-up Run-in Period Placebo Once Daily At least 3 hypoglycemic events during 28 days after last dose 21-day run-in period despite adhering to consistent dietary management > 90% completed 16-week double-blind All eligible participants entered

the OLE treatment period Key Trial Entry Criteria Primary Endpoints Hypoglycemic Events Definitions • Has undergone Roux-en-Y gastric bypass (RYGB) at • Composite of Level 2 (SMBG) and Level 3 • Level 2: glucose <54mg/dL least

12 months prior to screening visit hypoglycemic events • Level 3: events characterized by altered mental • Has a clinical diagnosis of PBH • Safety and tolerability and/or physical function requiring assistance Secondary Endpoints

• Level 2 hypoglycemic events (SMBG) • Level 2 hypoglycemic events (CGM) • Level 3 hypoglycemic events 6 SMBG: self-monitoring blood glucose; CGM: continuous glucose monitoring.

LUCIDITY Met Primary Endpoint Statistically significant 55% reduction in

composite rate of Level 2 and Level 3 hypoglycemic events compared to placebo Composite Level 2/3 Hypoglycemic Event Rate Reduction vs. Placebo, Week 16 (ITT, N=78) 100 90 80 Primary Analysis 70 55% Reduction Rate ratio: 0.45 (95% CI, 0.32, 0.63) 60

p=0.000003 p=0.000003 50 40 30 20 10 0 Avexitide 90 mg once daily 7 LS Mean % Reduction vs Placebo

LUCIDITY Met All Secondary Endpoints Consistent, highly statistically

significant, and clinically meaningful reductions ü ü ü Level 2 Level 2 Level 3 hypoglycemic hypoglycemic hypoglycemic events (SMBG) events (CGM) events 8

Avexitide was Generally Well-Tolerated with a Favorable Safety Profile

Through 16 Weeks • Adverse events were generally mild or moderate • No treatment-related serious adverse events • Most common adverse events were diarrhea, injection site erythema, and injection site bruising • No changes in

body weight with avexitide or placebo Safety profile consistent with that observed across all PBH clinical trials completed to date 9

The Burden of PBH Marilyn Tan, MD, FACE Principal Investigator of the

LUCIDITY clinical trial and Clinical Professor of Medicine at Stanford University School of Medicine Relevant Disclosures: Dr. Tan has received research payments from Amylyx Pharmaceuticals as primary investigator and received consulting

payments.

Post-Bariatric Hypoglycemia (PBH): A Chronic, Debilitating Condition

with High Unmet Need 1 ~160,000 People Currently Living with PBH in the U.S. No approved treatment options PBH Can be Dangerous and Life-Altering Hypoglycemic events can Can feel like a constant cycle Can affect someone’s ability In one study,

over 90% of cause cognitive impairment, of highs and lows with sudden to work, drive, function people with PBH described loss of consciousness, and and unpredictable crashes, independently, care for others, themselves as living with a even seizures

because the with limited options to or even be alone safely disability, speaking to the brain is not getting enough manage it incredible burden the glucose (neuroglycopenia) condition can have on daily 2 living Living with PBH “I pass out

multiple times a “I lost my driver’s license “I'm afraid to watch my “It affected my ability to work week. My lows are averaging since I am unaware of own kids at the pool and take care of my family.” 4-5 times a

day.” my lows.” because I might pass out.” 11 PBH=post-bariatric hypoglycemia; 1. Craig CM, et al. Surg Obes Relat Dis. 2026;22(6):674-683. 2. Craig CM and McLaughlin TL. Surg Obes Relat Dis. 2021 Nov;17(11):1865-1872.

Avexitide, an Investigational, First-in-Class GLP-1 Receptor

Antagonist, Targets a Central Pathway of PBH Pathophysiology GLP-1 Receptor Antagonism 1 2 3 4 Hypersecretion of Insulin Avexitide Binds to Mitigates Insulin Hypersecretion Altered Stomach Results in Recurrent, Rapid GLP-1 Receptor and Promotes

Glucose Drops in Blood Glucose Stabilization Insulin Pancreas GLP-1 Islet Insulin Beta Cells Receptor Intestine Stable Blood Meal Meal GLP-1 Glucose Response +10x increase Avexitide in GLP-1 Rapid Drop in Blood Glucose levels TIME TIME Altered

nutrient transit This exaggerated GLP-1 Avexitide binds to the GLP-1 Decreased insulin secretion due to anatomical changes secretion leads to abnormally receptor on pancreatic islet and stabilized glucose levels associated with bariatric surgery

high insulin levels in the beta cells to reduce the resulting from inhibition of the (e.g., Roux-en-Y gastric bypass) bloodstream, and subsequent effects of excessive effect of exaggerated GLP-1 leads to exaggerated GLP-1 hypoglycemia GLP-1

signaling secretion in people with PBH GLP-1=glucagon-like peptide-1; PBH=post-bariatric hypoglycemia; 1. Sheehan A, Patti ME. Diabetes Metab Syndr Obes. 2020;13:4469-4482; 2. Craig CM, et al. Diabetes Obes Metab. 2017; 1-10. 3. Thorens B,. et al.

Diabetes.1993;42(11):1678-1682. 4. Craig CM, et al. Diabetes Obes Metab. 2018;20(2):352-361. 5. Smith NK, et al. Neurochem Int. 2019;128:94-105. 12 6. Meloni AR, et al. Diabetes Obes Metab. 2013;15(1):15-27. 7. Craig CM, et al. Diabetologia.

2017;60(3):531-540. 8. Craig C, et al. J Endocr Soc. 2022;6(Suppl 1):A349. BLOOD SUGAR LEVEL BLOOD SUGAR LEVEL

Avexitide has the Potential to be a First-in-Class Treatment for PBH

Phase 3 LUCIDITY Trial Topline Data Summary Patient Impact Avexitide met primary and secondary endpoints Preventing a single Level 2 or Level 3 hypoglycemic demonstrating statistically significant and event could enable someone to care for their

child, clinically meaningful reductions in both SMBG function independently, and prevent potentially and CGM Level 2 and Level 3 hypoglycemic catastrophic consequences, such as a seizure, car events accident, or loss of consciousness Avexitide was

generally well-tolerated with a High unmet need for an FDA-approved treatment for favorable safety profile across all PBH clinical PBH, a disease with no approved therapies trials to date ~160K people living with PBH in the U.S. who require Builds

on positive results of five prior clinical medical management despite the current standard of trials of avexitide in PBH, including statistically care, nutrition therapy significant reductions in hypoglycemic events and stabilization of blood

glucose 13

Next Steps Josh Cohen Co-Chief Executive Officer & Co-Founder of

Amylyx Justin Klee Co-Chief Executive Officer & Co-Founder of Amylyx

Preparing for NDA Submission and Potential Commercialization with

Urgency Disease State Education Regulatory Submission Work ü ü Campaign Launched Already Underway Continuing to Gain Key ü Insights into the PBH Market Building Medical Affairs and ü Commercial Organization with Key Hires

Leadership team tenured in rare disease, global regulatory approval, and commercial launch experience 15

Avexitide Path to Potential Commercial Launch in 2027 Strong IP

position with ü patent rights through 2027 2037, potential for By End of 2026 Anticipated additional term through commercial August 2026 Expected NDA Patent Term Extensions launch in 2027, submission to Announced positive if approved the FDA

Granted Orphan Drug topline data Designation and positioned for NCE exclusivity 16 16 IP=intellectual property; NCE=new chemical entities.

Q&A

GRAPHIC

Filename: g184004ex99_1p10g1.jpg · Sequence: 6

Binary file (245918 bytes)

Download g184004ex99_1p10g1.jpg

GRAPHIC

Filename: g184004ex99_1p11g1.jpg · Sequence: 7

Binary file (432275 bytes)

Download g184004ex99_1p11g1.jpg

GRAPHIC

Filename: g184004ex99_1p12g1.jpg · Sequence: 8

Binary file (503320 bytes)

Download g184004ex99_1p12g1.jpg

GRAPHIC

Filename: g184004ex99_1p13g1.jpg · Sequence: 9

Binary file (360339 bytes)

Download g184004ex99_1p13g1.jpg

GRAPHIC

Filename: g184004ex99_1p14g1.jpg · Sequence: 10

Binary file (192098 bytes)

Download g184004ex99_1p14g1.jpg

GRAPHIC

Filename: g184004ex99_1p15g1.jpg · Sequence: 11

Binary file (394723 bytes)

Download g184004ex99_1p15g1.jpg

GRAPHIC

Filename: g184004ex99_1p16g1.jpg · Sequence: 12

Binary file (195709 bytes)

Download g184004ex99_1p16g1.jpg

GRAPHIC

Filename: g184004ex99_1p17g1.jpg · Sequence: 13

Binary file (99591 bytes)

Download g184004ex99_1p17g1.jpg

GRAPHIC

Filename: g184004ex99_1p1g1.jpg · Sequence: 14

Binary file (367855 bytes)

Download g184004ex99_1p1g1.jpg

GRAPHIC

Filename: g184004ex99_1p2g1.jpg · Sequence: 15

Binary file (165151 bytes)

Download g184004ex99_1p2g1.jpg

GRAPHIC

Filename: g184004ex99_1p3g1.jpg · Sequence: 16

Binary file (572728 bytes)

Download g184004ex99_1p3g1.jpg

GRAPHIC

Filename: g184004ex99_1p4g1.jpg · Sequence: 17

Binary file (199818 bytes)

Download g184004ex99_1p4g1.jpg

GRAPHIC

Filename: g184004ex99_1p5g1.jpg · Sequence: 18

Binary file (399471 bytes)

Download g184004ex99_1p5g1.jpg

GRAPHIC

Filename: g184004ex99_1p6g1.jpg · Sequence: 19

Binary file (280757 bytes)

Download g184004ex99_1p6g1.jpg

GRAPHIC

Filename: g184004ex99_1p7g1.jpg · Sequence: 20

Binary file (177315 bytes)

Download g184004ex99_1p7g1.jpg

GRAPHIC

Filename: g184004ex99_1p8g1.jpg · Sequence: 21

Binary file (199281 bytes)

Download g184004ex99_1p8g1.jpg

GRAPHIC

Filename: g184004ex99_1p9g1.jpg · Sequence: 22

Binary file (237236 bytes)

Download g184004ex99_1p9g1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 24

v3.26.1

Document and Entity Information

Aug. 18, 2026

Cover [Abstract]

Amendment Flag

false

Entity Central Index Key

0001658551

Document Type

8-K

Document Period End Date

Aug. 18, 2026

Entity Registrant Name

AMYLYX PHARMACEUTICALS, INC.

Entity Incorporation State Country Code

Entity File Number

001-41199

Entity Tax Identification Number

46-4600503

Entity Address, Address Line One

55 Cambridge Parkway

Entity Address, Address Line Two

Suite 6W

Entity Address, City or Town

Cambridge

Entity Address, State or Province

Entity Address, Postal Zip Code

02142

City Area Code

(617)

Local Phone Number

682-0917

Written Communications

false

Soliciting Material

false

Pre Commencement Tender Offer

false

Pre Commencement Issuer Tender Offer

false

Security 12b Title

Common Stock, $0.0001 par value per share

Trading Symbol

AMLX

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration